Friday, September 09, 2022 10:10:03 AM
1- I very much doubt this would attract our CEO's attention and
2- I believe that, it says to potential buyer that waiting for her to capitulate is what is smart to do.
It is obvious our leader just wait for FDA's conclusion relative to formula. Let's hope everything goes as expected and no delays (or worst) lies ahead.
Even then, the CEO will have to change her attitude toward the value of addressing mothers directly.
I however doubt she can do that, firmly believing that lining up a product on shelves is enough.
Patiently,
Roger
Recent BABYF News
- Nutrition Firm Expanding into the Fast Growing Kids Market • AllPennyStocks.com • 08/03/2023 04:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM